Key Highlights

● DGX closed at $231.07 on 9 October 2026, below every recent named broker target, which sit between $245 and $260.

● Market data shows a $237.85 mean from 12 analysts, while the second data set shows a $247.73 mean from 17 analysts, so no upside figure is presented.

● Market data records one Strong Buy, five Buy and six Hold ratings with no Sell, a Moderate Buy consensus.

● Barclays raised its target to $260 from $250 on 7 October, and Truist raised to $260 while keeping Hold on 21 September.

Quest Diagnostics Incorporated (NYSE:DGX) is a constituent of the S&P 500. The shares closed at $231.07 on Friday 9 October 2026. Several brokers have raised their targets in recent weeks, but the published consensus figures do not line up cleanly.

What Is the Latest Analyst Price Target?

The two data sets do not line up cleanly: market data shows a mean of $237.85 from 12 analysts, with a range of $200 to $260, while the second data set shows a mean of $247.73 and a median of $250 from 17 analysts, though its page carried a price header dated 2 October and targets last updated on 23 September. Every recent named broker target, between $245 and $260, sits above market data's mean, which suggests older, lower targets may be dragging that figure down. No upside figure is presented.

What Are Wall Street Analysts Saying?

Market data records one Strong Buy, five Buy and six Hold ratings with no Sell ratings, a consensus of Moderate Buy. Named broker actions are mostly upward revisions. Barclays raised its target from $250 to $260 with an Overweight rating on 7 October, and Truist raised its target from $250 to $260 while keeping a Hold rating on 21 September.

UBS lifted its target from $232 to $245 with a Neutral rating on 8 September. In July, JPMorgan raised its target from $220 to $250 with a Neutral rating, Mizuho moved from $235 to $260 with Outperform, and Robert W. Baird went from $236 to $255 with a Neutral rating. Argus set a $260 target and Jefferies reiterated Buy with a $245 target.

What Could Help the Stock Reach the Price Target?

Whatever the precise consensus, recent individual targets are all above the $231.07 price, so brokers broadly see room for gains. The direction of revisions has been upwards, including at brokers with only Neutral or Hold ratings such as JPMorgan, Truist and UBS. If the company continues to meet or beat expectations, further increases in forecasts could follow.

What Could Prevent the Stock Reaching the Target?

Half of the analysts counted by market data rate the shares Hold, indicating that many are not convinced of a strong re-rating. The low end of the published range, $200 to $204 depending on the provider, shows that some analysts hold more cautious views. Diagnostic services businesses can be affected by testing volumes, reimbursement and pricing pressures, labour costs and the wider healthcare policy environment.

What Should Investors Watch Next?

Items to watch include whether the data sets refresh their consensus figures, whether further brokers follow Barclays in raising targets, and how the shares trade against the $245 to $260 area where recent targets cluster.

Quest's Recent Targets Cluster Above Both Provider Means

Quest closed at $231.07 on 9 October 2026, and every recent named target, between $245 and $260, sits above market data's $237.85 mean, which suggests older, lower targets may be dragging that figure down. The direction of revisions has been upward, including at Neutral or Hold-rated brokers such as JPMorgan, Truist and UBS, but half of the analysts counted in market data rate the shares Hold and the low end of the range is $200 to $204 depending on the data set.